We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Nurix Stock Up 29% in a Month: Here's What You Should Know
Read MoreHide Full Article
Key Takeaways
NRIX has gained 28.6% in a month after announcing a Roche collaboration for bexobrutideg development.
Nurix can receive $700M upfront and up to $2.3B in milestones, while sharing U.S. profits and losses.
NRIX's bexobrutideg is expected to enter phase III in second-line CLL later in 2026.
Shares of Nurix Therapeutics (NRIX - Free Report) have seen a sharp increase over the past month, primarily driven by growing investor optimism about the company’s recently announced collaboration with Swiss pharma giant Roche (RHHBY - Free Report) .
NRIX’s Price Performance
Shares of Nurix have rallied 28.6% in the past month compared with the industry’s increase of 2.5%.
Image Source: Zacks Investment Research
Earlier this month, the companies signed an exclusive licensing and collaboration agreement to co-develop and co-commercialize one of Nurix’s lead pipeline candidates, bexobrutideg (NX-5948), across various malignant hematology, immunology and neurology indications.
Per the deal, Nurix is entitled to receive $700 million upfront and could earn up to $2.3 billion in total through development, regulatory, and commercial milestone payments from RHHBY. While Nurix will fund 40% of development costs, Roche will be covering the remaining 60%.
However, the companies will equally share all profits and losses from net sales of the product upon potential approval and launch in the United States. In ex-U.S. markets, Roche will solely lead all commercialization activities, and Nurix will receive tiered royalties ranging from the low to high-teens
The partnership is looking to build on Nurix’s pioneering expertise in targeted protein degradation with Roche’s leading portfolio of B-cell targeted therapies and clinical and commercial infrastructure.
More on NRIX’s Bexobrutideg Development
Bexobrutideg is an investigational, orally bioavailable, brain-penetrant Bruton’s tyrosine kinase (BTK) degrader being developed for the treatment of relapsed or refractory B-cell malignancies, as well as immunology and neurology indications. It uses a novel protein degradation mechanism that eliminates BTK rather than simply inhibiting it, potentially overcoming resistance associated with currently available BTK inhibitors.
Bexobrutideg is expected to enter phase III testing in second-line chronic lymphocytic leukemia (CLL) later in 2026. Early clinical results suggest the therapy could deliver superior efficacy and tolerability compared with existing BTK inhibitors while potentially overcoming key resistance mechanisms.
Beyond oncology, the clinical development plan for bexobrutideg also includes expanding into neurology and immunology, with phase II studies planned in multiple sclerosis (MS) and chronic spontaneous urticaria (CSU).
NRIX’s Other Collaborations Deals
Nurix is also progressing several partnered programs with large drugmakers like Sanofi (SNY - Free Report) , Gilead (GILD - Free Report) and Pfizer.
While Sanofi is advancing the STAT6 degrader, NX-3911, into clinical testing, Gilead is evaluating the IRAK4 degrader, GS-6791, in a phase I study. If these programs demonstrate encouraging clinical results, Nurix can choose to co-develop them and share U.S. profits. The company also expects to receive certain milestone payments from its collaborations with Gilead, Sanofi and Pfizer.
View the Zacks #1 Rank List
Image: Bigstock
Nurix Stock Up 29% in a Month: Here's What You Should Know
Key Takeaways
Shares of Nurix Therapeutics (NRIX - Free Report) have seen a sharp increase over the past month, primarily driven by growing investor optimism about the company’s recently announced collaboration with Swiss pharma giant Roche (RHHBY - Free Report) .
NRIX’s Price Performance
Shares of Nurix have rallied 28.6% in the past month compared with the industry’s increase of 2.5%.
Image Source: Zacks Investment Research
Earlier this month, the companies signed an exclusive licensing and collaboration agreement to co-develop and co-commercialize one of Nurix’s lead pipeline candidates, bexobrutideg (NX-5948), across various malignant hematology, immunology and neurology indications.
Per the deal, Nurix is entitled to receive $700 million upfront and could earn up to $2.3 billion in total through development, regulatory, and commercial milestone payments from RHHBY. While Nurix will fund 40% of development costs, Roche will be covering the remaining 60%.
However, the companies will equally share all profits and losses from net sales of the product upon potential approval and launch in the United States. In ex-U.S. markets, Roche will solely lead all commercialization activities, and Nurix will receive tiered royalties ranging from the low to high-teens
The partnership is looking to build on Nurix’s pioneering expertise in targeted protein degradation with Roche’s leading portfolio of B-cell targeted therapies and clinical and commercial infrastructure.
More on NRIX’s Bexobrutideg Development
Bexobrutideg is an investigational, orally bioavailable, brain-penetrant Bruton’s tyrosine kinase (BTK) degrader being developed for the treatment of relapsed or refractory B-cell malignancies, as well as immunology and neurology indications. It uses a novel protein degradation mechanism that eliminates BTK rather than simply inhibiting it, potentially overcoming resistance associated with currently available BTK inhibitors.
Bexobrutideg is expected to enter phase III testing in second-line chronic lymphocytic leukemia (CLL) later in 2026. Early clinical results suggest the therapy could deliver superior efficacy and tolerability compared with existing BTK inhibitors while potentially overcoming key resistance mechanisms.
Beyond oncology, the clinical development plan for bexobrutideg also includes expanding into neurology and immunology, with phase II studies planned in multiple sclerosis (MS) and chronic spontaneous urticaria (CSU).
NRIX’s Other Collaborations Deals
Nurix is also progressing several partnered programs with large drugmakers like Sanofi (SNY - Free Report) , Gilead (GILD - Free Report) and Pfizer.
While Sanofi is advancing the STAT6 degrader, NX-3911, into clinical testing, Gilead is evaluating the IRAK4 degrader, GS-6791, in a phase I study. If these programs demonstrate encouraging clinical results, Nurix can choose to co-develop them and share U.S. profits. The company also expects to receive certain milestone payments from its collaborations with Gilead, Sanofi and Pfizer.
Nurix Therapeutics, Inc. Price
Nurix Therapeutics, Inc. price | Nurix Therapeutics, Inc. Quote
NRIX’s Zacks Rank
Nurix currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.